Merck plans to pay $1.3 billion in cash upfront to acquire the company, with a potential $1.7 billion in additional milestone payments.
This marks Merck’s further expansion into the eye care market, which it had initially abandoned a decade ago. Its venture arm was already an investor in EyeBio, according to the report.
EyeBio’s lead medication is Restoret, which treats eye conditions, including a form of age-related macular degeneration that leads to blurred vision and potential blindness.
The drug is also in development for wet AMD, a condition that 2 million people in the U.S. suffer from.
Competitors Regeneron Pharmaceuticals Eylea and Roche brought in $5.9 billion in sales and $2.7 billion in sales, respectively, for their wet AMD medications in 2023.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.